<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672553</url>
  </required_header>
  <id_info>
    <org_study_id>2011-12</org_study_id>
    <nct_id>NCT02672553</nct_id>
  </id_info>
  <brief_title>EDWARDS INTUITY Valve System CADENCE-MIS Study</brief_title>
  <acronym>CADENCE-MIS</acronym>
  <official_title>A Randomized Comparison of the EDWARDS INTUITY Valve System anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve Replacement Using Minimally InvaSive Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to compare the EDWARDS INTUITY valve system in a minimal invasive
      surgical approach (MIS) with any commercially available aortic bioprosthesis in standard full
      sternotomy surgical approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study to compare the cross-clamp time (XCT) and cardiopulmonary bypass
      time (CPBT) of the EDWARDS INTUITY valve system in a minimally invasive surgical approach
      (MIS) with any commercially available aortic bioprosthesis in standard full sternotomy
      surgical approach, in patients with logistic EuroScore &lt; 20 undergoing elective isolated
      aortic valve replacement (AVR) surgery.

      Additionally, the aim is to gather sufficient data to quantify the effect size of short term
      patient benefit outcomes previously identified from literature and to explore additional
      healthcare resource utilization endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Subject Time Spent on Cardiopulmonary Cross Clamp</measure>
    <time_frame>At time of surgery; an average of 1 hour</time_frame>
    <description>Cardiopulmonary cross clamp time is the amount of time that the patient's aorta (blood vessel) is clamped by a surgical instrument used in cardiac surgery. This allows the normal blood flow to be sent to an artificial heart and lung machine to keep it at a constant temperature and oxygen level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Amount of Time Subject Spent on Cardiopulmonary Bypass</measure>
    <time_frame>At time of surgery; an average of 1 hour</time_frame>
    <description>Cardiopulmonary bypass time is the amount of time that the patient's blood circulates through an artificial heart and lung machine during cardiac surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at 2 Years.</measure>
    <time_frame>Baseline and 2 Years.</time_frame>
    <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Average Mean Gradients (mmHg) Measurements Over Time.</measure>
    <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
    <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Average Peak Gradients (mmHg) Measurements Over Time.</measure>
    <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
    <description>Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Effective Orifice Area (EOA) Measurement Over Time.</measure>
    <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
    <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Paravalvular Leak Over Time.</measure>
    <time_frame>Discharge, 30 days, 3 month, 1 year</time_frame>
    <description>Number of subjects who experienced a Paravalvular Leak shown over various time points.
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion of Edwards INTUITY Surgical Aortic Valve to Control Surgical Aortic Heart Valves During Surgery.</measure>
    <time_frame>Prior to Surgery</time_frame>
    <description>Subjects randomized to the Edwards INTUITY group that were converted to the control group and received commercially available surgical aortic heart valves during surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Required a Thoracic Resternotomy Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of Subjects who had a surgical opening of their chest after their initial aortic heart valve surgery shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Received a Permanent Pacemaker Over Time.</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of Subjects who received a Permanent Pacemaker shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Paravalvular Leak &gt; or Equal to 3+ and/or Requiring Intervention Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Paravalvular Leak shown over various time points.
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Experienced Major Bleeding Over Time.</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced Major Bleeding shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Experienced Respiratory Failure Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Respiratory Failure shown over various time points. Respiratory failure happens when not enough oxygen passes from your lungs to your blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Cerebral Vascular Accident or Permanent Stroke Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Cerebral Vascular Accident or Permanent Stroke shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Renal Failure Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced Renal (kidney) Failure shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Endocarditis Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced Endocarditis shown over various time points. Endocarditis is an infection of the endocardium, which is the inner lining of your heart chambers and heart valves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Deep Sternal Would Infection Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Deep Sternal Wound Infection shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Myocardial Infarction Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Myocardial Infarction shown over various time points. A Myocardial infarction, commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Thromboembolism Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Thromboembolism shown over various time points. A thromboembolism is an obstruction of a blood vessel by a blood clot that has become dislodged from another site in the circulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Cardiac Tamponade Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Cardiac Tamponade shown over various time points. Cardiac tamponade is when fluid in the pericardium (the sac around the heart) builds up and results in compression (squeezing) of the heart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With a Cardiac Reoperation for Any Reason Over Time</measure>
    <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
    <description>Number of subjects who experienced a Cardiac reoperation for any reason shown over various time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion of Subjects Undergoing Minimally Invasive Surgical Incision to Full Sternotomy for the Randomized to Edwards INTUITY Group During Surgery.</measure>
    <time_frame>Prior to Surgery</time_frame>
    <description>Subjects Randomized to Edwards INTUITY Group's Surgical Aortic Valve undergoing Minimally Invasive Surgical incision being converted to a Full Sternotomy open procedure During Surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Average Score on the EQ-5D - Quality of Life Questionnaire Over Time</measure>
    <time_frame>Baseline, 30 days, 3 Months, 1 Year</time_frame>
    <description>The EuroQol-5 Dimension (EQ-5D) is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Average Score SF-12 - Quality of Life Questionnaire Over Time</measure>
    <time_frame>Baseline, 30 days, 3 Months, 1 Year</time_frame>
    <description>Subject's Average Score at Baseline and at each follow-up interval until 2 year - SF-12.
The Medical Outcomes Study Short-Form 12 (SF-12) - Physical Component Summary (PCS) and Mental Component Summary (MCS).
The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worse health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Average Score on the KCCQ - Quality of Life Questionnaire Over Time</measure>
    <time_frame>Baseline, 30 days, 3 Months, 1 Year</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status. Subjects took this questionnaire at Baseline, 30 days, 3 Months,and 1 Year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization</measure>
    <time_frame>Day of surgical procedure through discharge from the hospital, an average of 1.5 weeks</time_frame>
    <description>The average amount of time the subjects spent in the intensive care unit, the intermediate care length of stay, and the average total length of hospital stay after their heart valve replacement procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Effective Orifice Area Index (EOAI) Measurement Over Time.</measure>
    <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
    <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Aortic Valvular Regurgitation Over Time.</measure>
    <time_frame>Discharge, 30 days, 3 month, 1 year</time_frame>
    <description>Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
Higher numbers on the scale show a worsening outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>EDWARDS INTUITY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EDWARDS INTUITY Valve System, Model 8300A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stented Aortic Bioprostheses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stented Aortic Bioprostheses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EDWARDS INTUITY Valve System, Model 8300A</intervention_name>
    <description>To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.</description>
    <arm_group_label>EDWARDS INTUITY</arm_group_label>
    <other_name>aortic stenosis</other_name>
    <other_name>stenosis-based insufficiency</other_name>
    <other_name>aortic valve replacement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stented Aortic Bioprostheses</intervention_name>
    <description>In comparison to control valves available on the market undergoing FS-AVR</description>
    <arm_group_label>Stented Aortic Bioprostheses</arm_group_label>
    <other_name>aortic stenosis</other_name>
    <other_name>stenosis-based insufficiency</other_name>
    <other_name>aortic valve replacement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. adult male or female ≥18 years of age

          2. symptomatic for aortic stenosis / mixed aortic stenosis and aortic insufficiency
             disease for which isolated surgical aortic valve replacement without concomitant
             procedures is planned

          3. EuroSCORE &lt;20

          4. NYHA Class ≥II

          5. Subject has signed and dated the investigation informed consent form prior to study
             specific procedures are performed

          6. Subject is geographically stable and agrees to participate in follow-up assessments as
             specified in the protocol and informed consent

        Exclusion (i.a.):

          1. pure aortic insufficiency

          2. previous cardiac surgery (involved FS or MIS approach)

          3. congenital true bicuspid / unicuspid aortic valve

          4. requires emergency surgery or has had emergency surgery for any reason

             ≤ 1 month before the intended treatment

          5. LVEF &lt;25%

          6. active endocarditis ≤ 6 months before the intended treatment

          7. acute MI ≤ 90 days before the intended treatment

          8. had a stroke or transient ischemic attack within six months prior to scheduled aortic
             valve replacement surgery

          9. oxygen or ventilator dependent

         10. life expectancy &lt; 12 months

         11. substance abuser

         12. Female subject is pregnant or lactating

         13. documented leukopenia (WBC &lt; 3.5x 103/μL), acute anemia (Hgb &lt; 10.0 gm/dL or &lt; 6.2
             mmol/L), thrombocytopenia (platelet count &lt; 100x 103/mL), or history of bleeding
             diathesis or coagulopathy

         14. hemodynamic or respiratory instability requiring inotropic support, mechanical
             circulatory support, or mechanical ventilation within 30 days of procedure

         15. documented echocardiographic evidence of intracardiac mass, thrombus or vegetation

         16. renal insufficiency as determined by Serum creatinine ≥ 200 μmol/L (2.27 mg/dL) at
             screening or end‐stage renal disease requiring chronic dialysis

         17. documented hyperparathyroidism

         18. currently participating in an investigational drug or device trial for which follow‐up
             has not yet been completed

         19. Minimally Invasive access to the heart is not possible due to anatomical constraints
             or any other pre‐existing condition

        Intra-operative Exclusion:

          1. has calcium on the anterior mitral leaflet which cannot be removed

          2. has extensive calcification of the aortic root

          3. Annular deformation which may or may not be caused by too extensive decalcification of
             the aortic annulus

          4. has left atrial thrombus

          5. The position of the coronary ostia relative to the EDWARDS INTUITY Valve would result
             in obstruction of blood flow

          6. hemodynamically unstable during the procedure requiring the procedure to be aborted
             prior to insertion of the study bioprosthesis and delivery system

          7. Study device is not available in the correct size for the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Borger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leipzig Heart Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://professional.heart.org/professional/General/UCM_423811_Classification-of-Functional-Capacity-and-Objective-Assessment.jsp</url>
    <description>New York Heart Association Classification</description>
  </link>
  <link>
    <url>https://euroqol.org/eq-5d-instruments/</url>
    <description>EuroQol Standardized Instrument (EQ-5D) developed to measure of health-related quality of life.</description>
  </link>
  <link>
    <url>http://cvoutcomes.org/pages/3214</url>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </link>
  <link>
    <url>https://campaign.optum.com/content/optum/en/optum-outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html</url>
    <description>Short Form Health Survey (SF-12) with 12 questions to measure functional health and well-being of patient's quality of life</description>
  </link>
  <results_reference>
    <citation>Borger MA, Dohmen PM, Knosalla C, Hammerschmidt R, Merk DR, Richter M, Doenst T, Conradi L, Treede H, Moustafine V, Holzhey DM, Duhay F, Strauch J. Haemodynamic benefits of rapid deployment aortic valve replacement via a minimally invasive approach: 1-year results of a prospective multicentre randomized controlled trial. Eur J Cardiothorac Surg. 2016 Oct;50(4):713-720. Epub 2016 Mar 2.</citation>
    <PMID>26935407</PMID>
  </results_reference>
  <results_reference>
    <citation>Borger MA, Moustafine V, Conradi L, Knosalla C, Richter M, Merk DR, Doenst T, Hammerschmidt R, Treede H, Dohmen P, Strauch JT. A randomized multicenter trial of minimally invasive rapid deployment versus conventional full sternotomy aortic valve replacement. Ann Thorac Surg. 2015 Jan;99(1):17-25. doi: 10.1016/j.athoracsur.2014.09.022. Epub 2014 Nov 20.</citation>
    <PMID>25441065</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <results_first_submitted>August 13, 2018</results_first_submitted>
  <results_first_submitted_qc>August 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2019</results_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Replacement</keyword>
  <keyword>Minimal Invasive Sternotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>As of this date no IPD plan has been formulated.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All eligible subjects recruited were randomized to each arm/group as 1:1 ratio at start.</recruitment_details>
      <pre_assignment_details>Three (3) of the subjects randomized to the Edwards INTUITY group were converted to the control group and received a commercially available surgical aortic heart valve via MIS and therefore these three (3) subjects could not be accurately categorized into the MIS-AVR or FS-AVR category and were excluded from the as intended (AI) cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
          <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
        </group>
        <group group_id="P2">
          <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
          <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent To Treated (ITT) Randomized Arm</title>
              <participants_list>
                <participants group_id="P1" count="49">Two (2) subjects randomized to Edwards INTUITY were intraoperative screen failures</participants>
                <participants group_id="P2" count="48">One (1) subject randomized to Control arm/group withdrew prior to study procedure</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>As Treated (AT) Randomized Arm/Group</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>As Intended (AI) Randomized Arm/Group</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Valve Explant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Conversion to Commercial Valve</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intraoperative screen failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3 of the subjs. randomized to the Edwards INTUITY group were converted to the control group and rec'd commercially available surgical aortic heart valves.From the overall,2 randomized to Edwards INTUITY &amp;1 randomized to control group were screen failures prior to procedure &amp; were excluded in the baseline analysis.Analysis is based on the AI cohort</population>
      <group_list>
        <group group_id="B1">
          <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
          <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
        </group>
        <group group_id="B2">
          <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
          <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.0" spread="5.3"/>
                    <measurement group_id="B2" value="74.2" spread="5.0"/>
                    <measurement group_id="B3" value="73.61" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Subject Time Spent on Cardiopulmonary Cross Clamp</title>
        <description>Cardiopulmonary cross clamp time is the amount of time that the patient's aorta (blood vessel) is clamped by a surgical instrument used in cardiac surgery. This allows the normal blood flow to be sent to an artificial heart and lung machine to keep it at a constant temperature and oxygen level.</description>
        <time_frame>At time of surgery; an average of 1 hour</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR.</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Median Subject Time Spent on Cardiopulmonary Cross Clamp</title>
          <description>Cardiopulmonary cross clamp time is the amount of time that the patient's aorta (blood vessel) is clamped by a surgical instrument used in cardiac surgery. This allows the normal blood flow to be sent to an artificial heart and lung machine to keep it at a constant temperature and oxygen level.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="16.0" upper_limit="115.0"/>
                    <measurement group_id="O2" value="47.5" lower_limit="32.0" upper_limit="123.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-12.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Amount of Time Subject Spent on Cardiopulmonary Bypass</title>
        <description>Cardiopulmonary bypass time is the amount of time that the patient's blood circulates through an artificial heart and lung machine during cardiac surgery.</description>
        <time_frame>At time of surgery; an average of 1 hour</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Median Amount of Time Subject Spent on Cardiopulmonary Bypass</title>
          <description>Cardiopulmonary bypass time is the amount of time that the patient's blood circulates through an artificial heart and lung machine during cardiac surgery.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="38.0" upper_limit="161.0"/>
                    <measurement group_id="O2" value="69.0" lower_limit="39.0" upper_limit="170.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2077</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-10.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at 2 Years.</title>
        <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
        <time_frame>Baseline and 2 Years.</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at 2 Years.</title>
          <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the ITT cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Average Mean Gradients (mmHg) Measurements Over Time.</title>
        <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
        <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Mean Gradients (mmHg) Measurements Over Time.</title>
          <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="15.9"/>
                    <measurement group_id="O2" value="45.4" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="5.4"/>
                    <measurement group_id="O2" value="10.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="4.2"/>
                    <measurement group_id="O2" value="9.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="4.2"/>
                    <measurement group_id="O2" value="10.3" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.9"/>
                    <measurement group_id="O2" value="11.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Average Peak Gradients (mmHg) Measurements Over Time.</title>
        <description>Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
        <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Peak Gradients (mmHg) Measurements Over Time.</title>
          <description>Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="23.7"/>
                    <measurement group_id="O2" value="75.4" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="9.5"/>
                    <measurement group_id="O2" value="21.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="7.8"/>
                    <measurement group_id="O2" value="17.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="7.6"/>
                    <measurement group_id="O2" value="18.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="5.3"/>
                    <measurement group_id="O2" value="21.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Effective Orifice Area (EOA) Measurement Over Time.</title>
        <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
        <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Effective Orifice Area (EOA) Measurement Over Time.</title>
          <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>centimeters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.6"/>
                    <measurement group_id="O2" value="1.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.5"/>
                    <measurement group_id="O2" value="2.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.5"/>
                    <measurement group_id="O2" value="1.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.5"/>
                    <measurement group_id="O2" value="1.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Paravalvular Leak Over Time.</title>
        <description>Number of subjects who experienced a Paravalvular Leak shown over various time points.
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
        <time_frame>Discharge, 30 days, 3 month, 1 year</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Paravalvular Leak Over Time.</title>
          <description>Number of subjects who experienced a Paravalvular Leak shown over various time points.
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conversion of Edwards INTUITY Surgical Aortic Valve to Control Surgical Aortic Heart Valves During Surgery.</title>
        <description>Subjects randomized to the Edwards INTUITY group that were converted to the control group and received commercially available surgical aortic heart valves during surgery.</description>
        <time_frame>Prior to Surgery</time_frame>
        <population>Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Conversion of Edwards INTUITY Surgical Aortic Valve to Control Surgical Aortic Heart Valves During Surgery.</title>
          <description>Subjects randomized to the Edwards INTUITY group that were converted to the control group and received commercially available surgical aortic heart valves during surgery.</description>
          <population>Analysis is based on the ITT cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Required a Thoracic Resternotomy Over Time</title>
        <description>Number of Subjects who had a surgical opening of their chest after their initial aortic heart valve surgery shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Required a Thoracic Resternotomy Over Time</title>
          <description>Number of Subjects who had a surgical opening of their chest after their initial aortic heart valve surgery shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Received a Permanent Pacemaker Over Time.</title>
        <description>Number of Subjects who received a Permanent Pacemaker shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Received a Permanent Pacemaker Over Time.</title>
          <description>Number of Subjects who received a Permanent Pacemaker shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Paravalvular Leak &gt; or Equal to 3+ and/or Requiring Intervention Over Time</title>
        <description>Number of subjects who experienced a Paravalvular Leak shown over various time points.
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Paravalvular Leak &gt; or Equal to 3+ and/or Requiring Intervention Over Time</title>
          <description>Number of subjects who experienced a Paravalvular Leak shown over various time points.
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Experienced Major Bleeding Over Time.</title>
        <description>Number of subjects who experienced Major Bleeding shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Experienced Major Bleeding Over Time.</title>
          <description>Number of subjects who experienced Major Bleeding shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Experienced Respiratory Failure Over Time</title>
        <description>Number of subjects who experienced a Respiratory Failure shown over various time points. Respiratory failure happens when not enough oxygen passes from your lungs to your blood.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Experienced Respiratory Failure Over Time</title>
          <description>Number of subjects who experienced a Respiratory Failure shown over various time points. Respiratory failure happens when not enough oxygen passes from your lungs to your blood.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Cerebral Vascular Accident or Permanent Stroke Over Time</title>
        <description>Number of subjects who experienced a Cerebral Vascular Accident or Permanent Stroke shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Cerebral Vascular Accident or Permanent Stroke Over Time</title>
          <description>Number of subjects who experienced a Cerebral Vascular Accident or Permanent Stroke shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Renal Failure Over Time</title>
        <description>Number of subjects who experienced Renal (kidney) Failure shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Renal Failure Over Time</title>
          <description>Number of subjects who experienced Renal (kidney) Failure shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Endocarditis Over Time</title>
        <description>Number of subjects who experienced Endocarditis shown over various time points. Endocarditis is an infection of the endocardium, which is the inner lining of your heart chambers and heart valves.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Endocarditis Over Time</title>
          <description>Number of subjects who experienced Endocarditis shown over various time points. Endocarditis is an infection of the endocardium, which is the inner lining of your heart chambers and heart valves.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Deep Sternal Would Infection Over Time</title>
        <description>Number of subjects who experienced a Deep Sternal Wound Infection shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Deep Sternal Would Infection Over Time</title>
          <description>Number of subjects who experienced a Deep Sternal Wound Infection shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Myocardial Infarction Over Time</title>
        <description>Number of subjects who experienced a Myocardial Infarction shown over various time points. A Myocardial infarction, commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Myocardial Infarction Over Time</title>
          <description>Number of subjects who experienced a Myocardial Infarction shown over various time points. A Myocardial infarction, commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Thromboembolism Over Time</title>
        <description>Number of subjects who experienced a Thromboembolism shown over various time points. A thromboembolism is an obstruction of a blood vessel by a blood clot that has become dislodged from another site in the circulation.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Thromboembolism Over Time</title>
          <description>Number of subjects who experienced a Thromboembolism shown over various time points. A thromboembolism is an obstruction of a blood vessel by a blood clot that has become dislodged from another site in the circulation.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Cardiac Tamponade Over Time</title>
        <description>Number of subjects who experienced a Cardiac Tamponade shown over various time points. Cardiac tamponade is when fluid in the pericardium (the sac around the heart) builds up and results in compression (squeezing) of the heart.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Cardiac Tamponade Over Time</title>
          <description>Number of subjects who experienced a Cardiac Tamponade shown over various time points. Cardiac tamponade is when fluid in the pericardium (the sac around the heart) builds up and results in compression (squeezing) of the heart.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With a Cardiac Reoperation for Any Reason Over Time</title>
        <description>Number of subjects who experienced a Cardiac reoperation for any reason shown over various time points.</description>
        <time_frame>30 days, 3 Months, 1 Year, 2 Years.</time_frame>
        <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With a Cardiac Reoperation for Any Reason Over Time</title>
          <description>Number of subjects who experienced a Cardiac reoperation for any reason shown over various time points.</description>
          <population>Cumulative number of subjects with an event by each time point. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conversion of Subjects Undergoing Minimally Invasive Surgical Incision to Full Sternotomy for the Randomized to Edwards INTUITY Group During Surgery.</title>
        <description>Subjects Randomized to Edwards INTUITY Group's Surgical Aortic Valve undergoing Minimally Invasive Surgical incision being converted to a Full Sternotomy open procedure During Surgery.</description>
        <time_frame>Prior to Surgery</time_frame>
        <population>Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Conversion of Subjects Undergoing Minimally Invasive Surgical Incision to Full Sternotomy for the Randomized to Edwards INTUITY Group During Surgery.</title>
          <description>Subjects Randomized to Edwards INTUITY Group's Surgical Aortic Valve undergoing Minimally Invasive Surgical incision being converted to a Full Sternotomy open procedure During Surgery.</description>
          <population>Analysis is based on the ITT cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Average Score on the EQ-5D - Quality of Life Questionnaire Over Time</title>
        <description>The EuroQol-5 Dimension (EQ-5D) is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.</description>
        <time_frame>Baseline, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported where data is available. Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Score on the EQ-5D - Quality of Life Questionnaire Over Time</title>
          <description>The EuroQol-5 Dimension (EQ-5D) is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.</description>
          <population>The outcome is reported where data is available. Analysis is based on the ITT cohort</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.900" spread="0.097"/>
                    <measurement group_id="O2" value="0.902" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.862" spread="0.080"/>
                    <measurement group_id="O2" value="0.902" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.908" spread="0.080"/>
                    <measurement group_id="O2" value="0.918" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.922" spread="0.086"/>
                    <measurement group_id="O2" value="0.925" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Average Score SF-12 - Quality of Life Questionnaire Over Time</title>
        <description>Subject's Average Score at Baseline and at each follow-up interval until 2 year - SF-12.
The Medical Outcomes Study Short-Form 12 (SF-12) - Physical Component Summary (PCS) and Mental Component Summary (MCS).
The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worse health status.</description>
        <time_frame>Baseline, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported where data is available. Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Score SF-12 - Quality of Life Questionnaire Over Time</title>
          <description>Subject's Average Score at Baseline and at each follow-up interval until 2 year - SF-12.
The Medical Outcomes Study Short-Form 12 (SF-12) - Physical Component Summary (PCS) and Mental Component Summary (MCS).
The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worse health status.</description>
          <population>The outcome is reported where data is available. Analysis is based on the ITT cohort</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.39" spread="9.18"/>
                    <measurement group_id="O2" value="40.79" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS - 30 day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.16" spread="10.08"/>
                    <measurement group_id="O2" value="38.45" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS - 3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.42" spread="8.19"/>
                    <measurement group_id="O2" value="43.95" spread="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS - 1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.84" spread="9.46"/>
                    <measurement group_id="O2" value="44.70" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.02" spread="12.85"/>
                    <measurement group_id="O2" value="50.07" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS - 30 day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.06" spread="12.88"/>
                    <measurement group_id="O2" value="50.26" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS - 3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.87" spread="11.28"/>
                    <measurement group_id="O2" value="51.37" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS - 1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.08" spread="8.80"/>
                    <measurement group_id="O2" value="52.46" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Average Score on the KCCQ - Quality of Life Questionnaire Over Time</title>
        <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status. Subjects took this questionnaire at Baseline, 30 days, 3 Months,and 1 Year.</description>
        <time_frame>Baseline, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported where data is available. Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Score on the KCCQ - Quality of Life Questionnaire Over Time</title>
          <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status. Subjects took this questionnaire at Baseline, 30 days, 3 Months,and 1 Year.</description>
          <population>The outcome is reported where data is available. Analysis is based on the ITT cohort</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.37" spread="24.79"/>
                    <measurement group_id="O2" value="61.33" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.81" spread="23.64"/>
                    <measurement group_id="O2" value="64.33" spread="24.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.32" spread="23.58"/>
                    <measurement group_id="O2" value="76.35" spread="19.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.85" spread="21.25"/>
                    <measurement group_id="O2" value="78.11" spread="21.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Care Utilization</title>
        <description>The average amount of time the subjects spent in the intensive care unit, the intermediate care length of stay, and the average total length of hospital stay after their heart valve replacement procedure.</description>
        <time_frame>Day of surgical procedure through discharge from the hospital, an average of 1.5 weeks</time_frame>
        <population>This outcome is reported for subjects where data is available. Analysis is based on the ITT cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Health Care Utilization</title>
          <description>The average amount of time the subjects spent in the intensive care unit, the intermediate care length of stay, and the average total length of hospital stay after their heart valve replacement procedure.</description>
          <population>This outcome is reported for subjects where data is available. Analysis is based on the ITT cohort</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Length of stay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="7.0"/>
                    <measurement group_id="O2" value="11.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU Length of stay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="5.4"/>
                    <measurement group_id="O2" value="1.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate Care Length of stay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.7"/>
                    <measurement group_id="O2" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Effective Orifice Area Index (EOAI) Measurement Over Time.</title>
        <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
        <time_frame>Baseline, Discharge, 30 days, 3 Months, 1 Year</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Effective Orifice Area Index (EOAI) Measurement Over Time.</title>
          <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>centimeters squared/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.3"/>
                    <measurement group_id="O2" value="1.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.3"/>
                    <measurement group_id="O2" value="1.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.2"/>
                    <measurement group_id="O2" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Aortic Valvular Regurgitation Over Time.</title>
        <description>Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
Higher numbers on the scale show a worsening outcome.</description>
        <time_frame>Discharge, 30 days, 3 month, 1 year</time_frame>
        <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
            <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Aortic Valvular Regurgitation Over Time.</title>
          <description>Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
Higher numbers on the scale show a worsening outcome.</description>
          <population>The outcome is reported for subjects where data is available. Analysis is based on the AI cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events occurring from baseline through two (2) years post implant</time_frame>
      <desc>Adverse event table is reported using ITT cohort</desc>
      <group_list>
        <group group_id="E1">
          <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
          <description>Subject who received an Edwards INTUITY surgical aortic heart valve undergoing MIS-AVR</description>
        </group>
        <group group_id="E2">
          <title>Control Group - Commercial Surgical Aortic Heart Valve</title>
          <description>Subject who received a commercially available surgical aortic heart valve undergoing FS-AVR</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BLEEDING - CARDIOVASCULAR - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>BLEEDING - GASTROINTESTINAL UPPER -MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>BLEEDING - NEUROLOGICAL - MAJOR (E.G. CVA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>BLEEDING - PERIPHERAL VASCULAR - MINOR (E.G. NOSEBLEEDS; HEMATOMAS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - OTHER - CENTRAL - NO PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - STROKE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - TRANSIENT ISCHEMIC ATTACK (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PAROXYSMAL ATRIAL FIBRILLATION (PAF)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 3RD DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PERSISTANT ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - SUPRAVENTRICULAR TACHYCARDIA (SVT)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - TACHYCARDIA - NON-VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - TACHYCARDIA - VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PERICARDIAL TAMPONADE - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>CARDIAC DECOMPENSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>REGURGITATION - MITRAL-INDETERMINATE-+4</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY (GALLBLADDER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL - INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK - +4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK WITH HEMOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>CANCER - NEWLY DIAGNOSED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>NONSPECIFIC, UNKNOWN, OR OTHER BODY SYSTEM - OTHER COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ALLERGIC REACTION - MEDICATION RELATED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>MULTI-SYSTEM ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR SKELETAL / DERMATOLOGIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>STERNAL WOUND/THORACIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>INFECTION /INFLAMMATION - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSIENT PSYCHOTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GENITOURINARY - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RENAL DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE - ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RENAL - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION (UTI)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PLEURAL EFFUSION - BILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INFECTION - PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE -PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - LEFT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE -COPD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASCULAR - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA - NON-BLEEDING RELATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ANEMIA - BLEEDING RELATED - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>BLEEDING - GASTROINTESTINAL LOWER -MINOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>BLEEDING - PULMONARY/RESPIRATORY MINOR (E.G. HEMOTHORAX)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>BLOOD/ LYMPHATIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA - PAROXYSMAL ATRIAL FIBRILLATION (PAF)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PERMANENT ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - TRANSIENT ISCHEMIC ATTACK (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 1ST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 2ND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 3RD DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PAROXYSMAL ATRIAL TACHYCARDIA (PAT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - SUPRAVENTRICULAR TACHYCARDIA (SVT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PERSISTANT ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - TACHYCARDIA - NON-VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL - INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK - +1</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>NONSPECIFIC, UNKNOWN, OR OTHER BODY SYSTEM - OTHER COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR SKELETAL / DERMATOLOGIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>INFECTION /INFLAMMATION - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSIENT PSYCHOTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE - ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>GENITOURINARY - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION (UTI)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PLEURAL EFFUSION - BILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - LEFT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>PULMONARY/RESPIRATORY - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE -COPD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INFECTION - PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE -OTHER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI’s site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Edwards, VP Clinical and Regulatory Affairs, HVT</name_or_title>
      <organization>Edwards Lifesciences, LLC</organization>
      <phone>949-250-2500 ext 1536</phone>
      <email>mary_edwards@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

